

Moshe Mittelman MD

Tel Aviv Sourasky Medical Center, and Sackler Faculty of
Medicine, Tel Aviv University, Israel

Professor Mittelman graduated from the Sackler School of Medicine in 1976, and served in the Israel Medical Corps (IDF), before completing a Residency in Internal Medicine at the Hasharon Hospital, Petah-Tikva, Israel. He later undertook a Combined Clinical and Research Fellowship Programme in Hematology and Oncology at the George Washington University Medical Center, Washington DC, USA, and The National Institutes of Health (NIH), Bethesda, USA. Professor Mittelman returned to Israel in 1989 and has since held several posts at the Hasharon Hospital and Tel Aviv Sourasky Medical Center. Moshe has also served as President of the Israel Society of Internal Medicine, Secretary of the Israel Society of Hematology, a Hematology Consultant for the Israel Ministry of Health, and is currently the President of the Israel Society of Hematology and Transfusion Medicine.

Among other academic and public duties, Prof Mittelman served as a member of the National Health Basket (Vaadat Sal) committee, and as a member of the Israel Medical Association (HARI) Scientific Committee. As a chairman of the Student Admission Committee of the Tel Aviv University Sackler School of Medicine, Dr Mittelman led the novel admission program, combining scholastic scores with personality and behaviour as evaluated parameters for medical school candidates. He has also served as a member of the National Council for the Prevention and Treatment of Cancer; a member of the Board of Directors of the Israel Medical Association (Haaguda) and as a consultant for biotechnology firms. As a biotech expert he is responsible for 2 patents, leading to start-up companies. He is currently the chief scientific officer of a biotech fund.

Professor Mittelman's research interests include basic and clinical aspects of multiple myeloma, stem cell disorders such as myelodysplastic syndromes (MDS) and myeloproliferative neoplasms (MPN) and basic and clinical effects of erythropoietin. He has co-authored more than 200 publications, including textbook chapters and articles, published in journals such as Blood, Journal of Clinical Oncology, Proceedings of the National Academy of Sciences, Haematologica, British Journal of Haematology and Experimental Hematology.

Later this year, Dr Mittelman will complete his term as Chairman, Department of Medicine, at the Tel Aviv Sourasky Medical Center, and will continue to serve as a hematology consultant, in addition to his post as a full clinical professor affiliated with the Sackler School of Medicine, Tel Aviv University.